{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "7db53c97",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.metrics.pairwise import cosine_distances\n",
    "import numpy\n",
    "from sklearn.metrics import f1_score,precision_score,recall_score\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "3020ea0e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Type': 'Comparison', 'Section_id': 'Eligibility', 'Primary_id': 'NCT00425854', 'Secondary_id': 'NCT01224678', 'Statement': 'Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over', 'Label': 'Contradiction'}\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "dev_path = \"E:/Professional Masters in Data Science/SEM 3/NLP/Project/Task-2-SemEval-2024-main/Task-2-SemEval-2024-main/training_data/dev.json\"\n",
    "with open(dev_path) as json_file:\n",
    "    dev = json.load(json_file)\n",
    "\n",
    "# Example instance\n",
    "print(dev[list(dev.keys())[1]])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "0444445b",
   "metadata": {},
   "outputs": [],
   "source": [
    "uuid_list = list(dev.keys())\n",
    "statements = []\n",
    "gold_dev_primary_evidence = []\n",
    "gold_dev_secondary_evidence = []\n",
    "for i in range(len(uuid_list)):\n",
    "  #Retrieve all statements from the development set\n",
    "  statements.append(dev[uuid_list[i]][\"Statement\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "406af643",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['there is a 13.2% difference between the results from the two the primary trial cohorts',\n",
       " 'Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over',\n",
       " 'a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis',\n",
       " 'the primary trial does not report the PFS or objective response rate of its patient cohort',\n",
       " 'Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial',\n",
       " 'only patients with a HER2-positive status can take part in the primary trial',\n",
       " 'the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months',\n",
       " 'Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .',\n",
       " 'the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease ',\n",
       " 'The only case of congestive heart failure in the primary trial occurred in cohort 1',\n",
       " 'The the primary trial results section reports two different measurements',\n",
       " 'T4 N2 M4 patients are eligible for the primary trial',\n",
       " 'The the primary trial results section reports two different measurements, for all 3 cohorts.',\n",
       " 'both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have',\n",
       " 'Patients must have a palpable carcinoma to be included in the primary trial',\n",
       " 'Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial',\n",
       " 'The shortest PFS in cohort 1 of the primary trial was less than 3 weeks',\n",
       " 'The adverse events section in the primary trial is reports the incidence rate of 12 different Aes',\n",
       " 'Diarrhoea is the most common adverse event in the primary trial and the secondary trial',\n",
       " 'to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer',\n",
       " 'ongoing flucytosine treatments are not permitted for participants of the primary trial',\n",
       " 'the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight',\n",
       " 'Only patients with triple negative breast cancer are eligible for the primary trial',\n",
       " 'most participants in the secondary trial and the primary trial did not suffer from Enterocolitis',\n",
       " 'The adverse events section in the primary trial is empty',\n",
       " 'there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial',\n",
       " 'adults and children can take part in the primary trial',\n",
       " 'Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial',\n",
       " 'Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.',\n",
       " 'the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.',\n",
       " 'None of the individual Aes recorded in the primary trial affect more than than one patient',\n",
       " 'there is a minimal difference between the results from the two the primary trial cohorts',\n",
       " 'to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.',\n",
       " 'The most common adverse event in the primary trial was skin infection',\n",
       " 'Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial',\n",
       " 'None of the individual Aes recorded in the primary trial affect more than 10% of the population.',\n",
       " 'Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion',\n",
       " 'the primary trial and the secondary trial use identical outcome measurements',\n",
       " 'Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression',\n",
       " 'A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm',\n",
       " 'the primary trial participants receive more than one type of medication during the study',\n",
       " 'the primary trial and the secondary trial do not report adverse events',\n",
       " 'ECOG score < 2 is necessary to be eligible for the primary trial',\n",
       " 'patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial',\n",
       " 'the secondary trial and the primary trial do not have the same inclusion and exclusion conditions',\n",
       " 'at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months',\n",
       " 'Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial',\n",
       " 'Syncope was the most common adverse event recorded in the primary trial',\n",
       " 'All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial',\n",
       " 'all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial',\n",
       " 'the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally',\n",
       " 'the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis',\n",
       " 'The results from the secondary trial and the primary trial are non-comparable',\n",
       " 'the primary trial and the secondary trial participants do not receive any medication orally',\n",
       " 'neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.',\n",
       " 'to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.',\n",
       " 'The shortest PFS in cohort 1 of the primary trial was 1.4 months below average',\n",
       " 'there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.',\n",
       " 'the primary trial reports the changes in the number of lesions for patients in its cohorts.',\n",
       " 'all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy',\n",
       " 'no cardiac or neural adverse events were recorded in the primary trial',\n",
       " 'Only adults can take part in the primary trial',\n",
       " 'there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1',\n",
       " 'All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months',\n",
       " 'the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.',\n",
       " 'Cohort 1 and 2 of the primary trial do not receive the same intervention',\n",
       " 'Patients with Extracranial metastases can be eligible for the primary trial',\n",
       " 'patients with a Malignant brain tumour diagnosis are excluded from the primary trial',\n",
       " 'ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry',\n",
       " 'There are more cases of Urosepsis in the primary trial than in the secondary trial',\n",
       " 'the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.',\n",
       " 'There were multiple patients which suffered Neutropenia in both cohorts of the primary trial',\n",
       " 'All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole',\n",
       " 'Patients must be able to undergo a PET scan to participate in the primary trial',\n",
       " 'There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study',\n",
       " 'the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention',\n",
       " 'a patient with a HER2-positive status can not take part in the primary trial',\n",
       " 'the primary trial and the secondary trial do not record any cardiac or infection related adverse events',\n",
       " 'none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events',\n",
       " 'Breast cancer patients must have documented stable disease to participate in the primary trial',\n",
       " 'All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed',\n",
       " 'several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2',\n",
       " 'the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.',\n",
       " 'the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer',\n",
       " '80% of patients in the primary trial received a placebo intervention',\n",
       " 'Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)',\n",
       " 'Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial',\n",
       " 'Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.',\n",
       " 'in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain',\n",
       " 'Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)',\n",
       " 'the primary trial and the secondary trial report their results using different units of measure',\n",
       " 'the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib',\n",
       " 'the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.',\n",
       " 'the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS',\n",
       " 'Infections were the most common adverse events recorded in the primary trial',\n",
       " 'neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts',\n",
       " 'the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response ',\n",
       " 'a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1',\n",
       " 'the secondary trial and the primary trial do not record the same metrics in their results section',\n",
       " 'eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial',\n",
       " 'Breast cancer patients must have documented progressive disease to participate in the primary trial',\n",
       " 'the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy',\n",
       " 'There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial',\n",
       " 'the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16',\n",
       " 'Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2',\n",
       " 'There is no adverse events section in the primary trial',\n",
       " 'Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger ',\n",
       " 'all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial',\n",
       " 'there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1',\n",
       " 'the primary trial and the secondary trial use comparable outcome measurements',\n",
       " 'Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible',\n",
       " 'the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally',\n",
       " 'the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort',\n",
       " 'All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months',\n",
       " 'Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles',\n",
       " 'Patients must have a Life expectancy of at least 1 year to enroll in the primary trial',\n",
       " 'the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts',\n",
       " 'Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.',\n",
       " 'Patients with stage 4 cancer are excluded from the primary trial',\n",
       " 'in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain',\n",
       " 'Only 6/67 patients in cohort 1 of the primary trial suffered adverse events',\n",
       " 'the primary trial and the secondary trial participants do not receive any medication by IV',\n",
       " 'in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin',\n",
       " 'none of the individual adverse events in the primary trial affect more than 100 patients.',\n",
       " 'to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.',\n",
       " '50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities ',\n",
       " 'patients must be able to receive medication orally to participate in the primary trial',\n",
       " 'the primary trial and the secondary trial report the same types of adverse events',\n",
       " 'under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response',\n",
       " 'T1 N0 M0 patients are eligible for the primary trial',\n",
       " 'the results of the secondary trial and the primary trial are non-comparable',\n",
       " 'both the primary trial cohorts receive identical doses of Docetaxel ',\n",
       " 'neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention',\n",
       " 'Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial',\n",
       " 'no cardiac or bowel-related adverse events were recorded in the primary trial',\n",
       " 'There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial',\n",
       " 'patients must have HER2- breast cancer to participate in the primary trial',\n",
       " 'the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate',\n",
       " 'The results from the secondary trial and the primary trial can be compared by changing the units from days to months',\n",
       " 'the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.',\n",
       " 'There is one case of Diarrhea in the secondary trial and none in the primary trial',\n",
       " 'Only cohort 1 patients of the primary trial are administered Ipatasertib',\n",
       " 'there were no recorded deaths in the primary trial cohorts.',\n",
       " 'One patient cohort in the primary trial received a placebo intervention',\n",
       " 'Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.',\n",
       " 'the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts',\n",
       " 'Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial',\n",
       " '50% of cohort 2 patients in the primary trial suffered Keratitis',\n",
       " 'Only patients with HER2+ve breast cancer are eligible for the primary trial',\n",
       " 'the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects',\n",
       " 'The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.',\n",
       " 'any patient eligible for the secondary trial will also be eligible for the primary trial ',\n",
       " 'ECOG score > 2 is necessary to be eligible for the primary trial',\n",
       " 'cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients',\n",
       " 'Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial',\n",
       " 'the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression',\n",
       " 'under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response',\n",
       " 'both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo',\n",
       " 'both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-',\n",
       " 'Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial',\n",
       " 'Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial',\n",
       " 'Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial',\n",
       " 'the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death',\n",
       " 'there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial',\n",
       " 'the primary trial reports the changes in tumor size for patients in its cohorts.',\n",
       " 'The least common adverse event in the primary trial was Constipation ',\n",
       " 'There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial',\n",
       " 'There were more total AEs in cohort 1 of  the primary trial than cohort 2',\n",
       " 'over 1/6 patients in cohort 1 of the primary trial suffered adverse events',\n",
       " 'There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial',\n",
       " 'There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts',\n",
       " 'Patients must have a Life expectancy of 75+ years to enroll in the primary trial',\n",
       " 'the primary trial and the secondary trial have non-comparable outcome measurements for their results',\n",
       " 'All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial',\n",
       " 'neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention',\n",
       " 'There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial',\n",
       " 'the primary trial participants receive Capecitabine less often than they receive Lapatinib',\n",
       " 'eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial',\n",
       " 'Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients',\n",
       " 'Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial',\n",
       " 'neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications',\n",
       " 'the primary trial and the secondary trial report their results as perecentages but use different units of measure.',\n",
       " 'the primary trial intervention protocol lasts a total of 14 days',\n",
       " 'all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy',\n",
       " 'There was one case of  Neutropenia in both cohorts of the primary trial',\n",
       " 'Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.',\n",
       " 'Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)',\n",
       " 'The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.',\n",
       " 'Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial',\n",
       " 'All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.',\n",
       " 'A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm',\n",
       " 'the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. ',\n",
       " 'Patients must be bedbound or severaly disabled to participate in the primary trial',\n",
       " 'the results of the secondary trial and the primary trial report the same outcome measures',\n",
       " 'the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.',\n",
       " 'The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.',\n",
       " 'the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any',\n",
       " 'the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.',\n",
       " 'the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse',\n",
       " 'All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions']"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "statements"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "409b6a39",
   "metadata": {},
   "outputs": [],
   "source": [
    "Results = {}\n",
    "path=\"E:/Professional Masters in Data Science/SEM 3/NLP/Project/Task-2-SemEval-2024-main/Task-2-SemEval-2024-main/training_data/CT json\"\n",
    "for i in range(len(uuid_list)):\n",
    "  primary_ctr_path = os.path.join(path,dev[uuid_list[i]][\"Primary_id\"]+\".json\")\n",
    "  with open(primary_ctr_path) as json_file:\n",
    "    primary_ctr = json.load(json_file)\n",
    "\n",
    "  #Retrieve the full section from the primary trial\n",
    "  primary_section = primary_ctr[dev[uuid_list[i]][\"Section_id\"]]\n",
    "\n",
    "  #Convert a primary section entries to a matrix of TF-IDF features.\n",
    "  vectorizer = TfidfVectorizer().fit(primary_section)\n",
    "  X_s = vectorizer.transform([statements[i]])\n",
    "  X_p = vectorizer.transform(primary_section)\n",
    "  #Compute the cosine similarity between the primary section entries and the statement\n",
    "  primary_scores = cosine_distances(X_s, X_p)\n",
    "  #Repeat for the secondary trial\n",
    "  if dev[uuid_list[i]][\"Type\"] == \"Comparison\":\n",
    "    secondary_ctr_path = os.path.join(path,dev[uuid_list[i]][\"Secondary_id\"]+\".json\")\n",
    "    with open(secondary_ctr_path) as json_file:\n",
    "      secondary_ctr = json.load(json_file)\n",
    "    secondary_section = secondary_ctr[dev[uuid_list[i]][\"Section_id\"]]\n",
    "    vectorizer = TfidfVectorizer().fit(secondary_section)\n",
    "    X_s = vectorizer.transform([statements[i]])\n",
    "    X_p = vectorizer.transform(secondary_section)\n",
    "    secondary_scores = cosine_distances(X_s, X_p)\n",
    "    #Combine and average the cosine distances of all entries from the relevant section of the primary and secondary trial\n",
    "    combined_scores = []\n",
    "    combined_scores.extend(secondary_scores[0])\n",
    "    combined_scores.extend(primary_scores[0])\n",
    "    score = numpy.average(combined_scores)\n",
    "    #If the cosine distance is gless than 0.9 the prediction is entailment\n",
    "    if score > 0.9:\n",
    "      Prediction = \"Contradiction\"\n",
    "    else:\n",
    "      Prediction = \"Entailment\"\n",
    "    Results[str(uuid_list[i])] = {\"Prediction\":Prediction}\n",
    "  else:\n",
    "    #If the cosine distance is greater than 0.9 the prediction is contradiction\n",
    "    score = numpy.average(primary_scores)\n",
    "    if score > 0.9:\n",
    "      Prediction = \"Contradiction\"\n",
    "    else:\n",
    "      Prediction = \"Entailment\"\n",
    "    Results[str(uuid_list[i])] = {\"Prediction\":Prediction}\n",
    "\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "6294a21a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'1adc970c-d433-44d0-aa09-d3834986f7a2': {'Prediction': 'Entailment'}, '6b9162d0-0816-46d4-81af-c60028dcc63b': {'Prediction': 'Entailment'}, '0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f': {'Prediction': 'Entailment'}, 'cc1f712a-2116-4e40-9810-f315e3fa5ff8': {'Prediction': 'Entailment'}, '904061c0-14fa-4f13-9118-9a41e24fa8eb': {'Prediction': 'Entailment'}, '43ee7645-ce1e-42d5-9a74-3e379f6f367b': {'Prediction': 'Entailment'}, '0cef8c8e-7986-46c7-a597-c5733a9899c0': {'Prediction': 'Entailment'}, '43ce26e5-03fa-4e9d-b0eb-6ea356295753': {'Prediction': 'Entailment'}, '3facad41-0221-42f8-834d-470e65c4aad5': {'Prediction': 'Entailment'}, '9cbc00e9-3a2d-4471-a93e-72c95132fb6a': {'Prediction': 'Entailment'}, '8b91cab9-d858-45f3-bf8d-3d6fc55b4818': {'Prediction': 'Entailment'}, '4a75574c-fa86-4e62-a210-81c7b98a3807': {'Prediction': 'Entailment'}, 'd0b50aeb-aad8-4a8d-aae6-5c58a7d382c7': {'Prediction': 'Entailment'}, 'b0b61978-57db-4a1c-812c-509e8b05f2dc': {'Prediction': 'Entailment'}, '24b85b44-b9e6-4c28-b3aa-1bd97102b7f1': {'Prediction': 'Entailment'}, 'fbb62216-2cf2-4813-ad41-12a86940610f': {'Prediction': 'Entailment'}, '961a956e-fece-4baa-a2ad-d3a5320bd9d2': {'Prediction': 'Entailment'}, '97fd111c-6969-43ab-93af-b3dff09960e5': {'Prediction': 'Entailment'}, 'eb1bfb08-eba0-4130-b328-00f56c0f84a6': {'Prediction': 'Entailment'}, 'b1219e71-fbf5-4bba-8a93-a27ae444e3e1': {'Prediction': 'Entailment'}, 'f10f3b84-e039-4a02-a98b-86d149d9a16f': {'Prediction': 'Entailment'}, '0ddb07ae-6e70-436d-8723-f609e59c57da': {'Prediction': 'Entailment'}, 'c10eea1a-5768-442d-ae07-20b4f8f4b583': {'Prediction': 'Entailment'}, '2ef186d0-b4ab-44de-b785-a63e9e95851a': {'Prediction': 'Entailment'}, 'fef5aedb-21c0-4130-b8a3-cb1df5017c7a': {'Prediction': 'Entailment'}, '2655c892-216e-4b96-a8f2-6f64403215c5': {'Prediction': 'Entailment'}, '2825d63b-8f22-4fb8-829f-9567845251c6': {'Prediction': 'Entailment'}, '6b35bc10-f591-4b84-abac-40a74be949fa': {'Prediction': 'Entailment'}, 'a5baab2c-9c32-4301-a574-4ba5a0c2eb00': {'Prediction': 'Entailment'}, '70677d5f-7022-404c-8410-d1f89366d92f': {'Prediction': 'Entailment'}, 'f46a7d27-a94f-4389-a1a0-4a8f5177b354': {'Prediction': 'Entailment'}, 'fe876bb0-7ce3-4197-81ad-920f1f77938e': {'Prediction': 'Entailment'}, 'f45ff82d-e0f5-456a-9d78-ddc2dc6ab929': {'Prediction': 'Entailment'}, '4f705481-5dd0-414c-b375-c56e8c235b42': {'Prediction': 'Entailment'}, '614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2': {'Prediction': 'Entailment'}, 'c09fa61c-967a-40ae-96b0-c87b7cde237b': {'Prediction': 'Entailment'}, '4309860d-042d-45a4-8a0a-a9fdd075247a': {'Prediction': 'Entailment'}, 'f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85': {'Prediction': 'Entailment'}, '59cd7909-00c3-4c23-9a08-a42dbc8eabdd': {'Prediction': 'Entailment'}, 'e6a4e9a6-56b8-4a30-9743-eb02688c090f': {'Prediction': 'Entailment'}, '82a3e542-f784-44d7-90f6-34d7e969283c': {'Prediction': 'Entailment'}, 'fb360514-14be-45ab-8b74-ea5a7eb181d7': {'Prediction': 'Entailment'}, '7137dec6-5c98-4156-8035-7bbaaf0b649d': {'Prediction': 'Entailment'}, '015dd869-db90-45a9-a951-9dc7dc2b2e01': {'Prediction': 'Entailment'}, '3a4003f6-ff1c-43d8-be48-f767266b2cf5': {'Prediction': 'Entailment'}, '47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7': {'Prediction': 'Entailment'}, 'f3cb9150-32c6-4877-9a87-4fac45a24948': {'Prediction': 'Entailment'}, '9d8b26d6-d574-4717-88b6-77458bc683f3': {'Prediction': 'Entailment'}, '51be7c95-8da4-419c-950c-91ebdd2c3fe5': {'Prediction': 'Entailment'}, '07042b0f-d422-49c3-8d53-81319927a4b3': {'Prediction': 'Entailment'}, '32361e21-ee57-4c34-9390-833ba5048a10': {'Prediction': 'Entailment'}, '88668508-dfd4-4a39-91cd-cf1654a6dfc4': {'Prediction': 'Entailment'}, 'dca4c9f7-bb2a-4f73-b390-93b7ced87c73': {'Prediction': 'Entailment'}, 'e7604382-09cd-43b4-998f-a51b33f25c5a': {'Prediction': 'Entailment'}, '75affd49-4905-4d43-9a5c-ef795281bac4': {'Prediction': 'Entailment'}, '2e76c74a-b6dd-47d8-a674-c1e80b0a3a65': {'Prediction': 'Entailment'}, '8c6314f7-34f5-42a7-ba66-b95d050a6315': {'Prediction': 'Entailment'}, 'f114846e-79d8-4712-add0-bb34b65d418f': {'Prediction': 'Entailment'}, '812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe': {'Prediction': 'Entailment'}, 'b1d28450-fc7d-496a-9c7c-bf711b28f8e4': {'Prediction': 'Entailment'}, 'c7dc582a-4a58-4cb5-b980-b2d2b6a128c3': {'Prediction': 'Entailment'}, 'a805f174-2707-4302-a195-05153ea8523e': {'Prediction': 'Entailment'}, 'e4aeb013-7713-4b73-acbd-f8379cc6a494': {'Prediction': 'Entailment'}, 'b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3': {'Prediction': 'Entailment'}, '2729a321-709b-4392-9604-dd7237bedb17': {'Prediction': 'Entailment'}, '8e9611fc-89f8-44cb-af09-8d71a13ca082': {'Prediction': 'Entailment'}, 'b9491012-49ba-4eb1-8230-1966f54ea012': {'Prediction': 'Entailment'}, '62e449ad-16b3-479d-94a5-ffc435b5e99c': {'Prediction': 'Entailment'}, '565d7982-aa9a-4c01-987c-1d67bc9c212d': {'Prediction': 'Entailment'}, '7271e0db-bb82-423f-ad95-5ffa84fab97e': {'Prediction': 'Entailment'}, '6402e13a-7cfb-4774-b7f9-80ecb79fda2a': {'Prediction': 'Entailment'}, '734423d5-4b47-4448-ab98-811015d626f0': {'Prediction': 'Entailment'}, 'e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd': {'Prediction': 'Entailment'}, '32ed503c-1cfd-44f6-b8bb-23d9d175d73d': {'Prediction': 'Entailment'}, '175044aa-72b1-405d-8506-30002f5098e4': {'Prediction': 'Entailment'}, '045ad91e-44fa-42cc-ac22-a7aab26a9009': {'Prediction': 'Entailment'}, '00822101-fa21-4a26-bf45-3b1f535da005': {'Prediction': 'Entailment'}, '06f798d1-2956-4903-83e9-58a41fa425f7': {'Prediction': 'Entailment'}, '8648c7df-582a-42a9-9330-414b2430ac56': {'Prediction': 'Entailment'}, '89f610a7-9e81-43a4-8c1e-5503233b2be1': {'Prediction': 'Entailment'}, 'b0046821-ba27-4a90-8869-cb708b843aa4': {'Prediction': 'Entailment'}, 'd1b217ae-76f3-4ba6-958e-5b2558703ba4': {'Prediction': 'Entailment'}, '8ddf8b88-6e06-4c71-9e28-45f73a637af0': {'Prediction': 'Entailment'}, '0ea29bd5-20be-40ea-8ad7-705d283d1d48': {'Prediction': 'Entailment'}, 'e147796d-2edd-42d1-ac53-300fb8bd5eb6': {'Prediction': 'Entailment'}, '6b33b4ae-36f2-4a53-a954-6f246f6e023d': {'Prediction': 'Entailment'}, '06fad978-1dc3-46f5-b45f-5ac6577f28b9': {'Prediction': 'Entailment'}, '878c09e7-3fd9-404e-921e-5b549e9578fb': {'Prediction': 'Entailment'}, '3a0c517d-9b9a-4497-9675-50ff12cd02b7': {'Prediction': 'Entailment'}, '9abb10d7-496e-44fd-915d-d86aedf6c9b6': {'Prediction': 'Entailment'}, '8460a212-8054-4bd2-b4e6-af1d137a2f79': {'Prediction': 'Entailment'}, 'a3390ae6-d41d-4dc7-899e-de9534adfd6b': {'Prediction': 'Entailment'}, '17bbea92-8f92-41f3-9b9d-cf6e62cf6798': {'Prediction': 'Entailment'}, '794269ca-e7ec-4a65-ace5-b0f24a8cdc15': {'Prediction': 'Entailment'}, '4dfff980-6a2b-4f01-9194-6ec831d6fed7': {'Prediction': 'Entailment'}, 'dc4c57b0-8c75-494e-81b0-3528df85ebff': {'Prediction': 'Entailment'}, '8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c': {'Prediction': 'Entailment'}, '251a20d8-2555-4929-9d01-c02311bdc93f': {'Prediction': 'Entailment'}, 'dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1': {'Prediction': 'Entailment'}, 'f0273b8c-460d-46fe-9c52-8ff4b08e439b': {'Prediction': 'Entailment'}, 'bc2024fc-5b39-4fa6-badf-f034d6fe8bb8': {'Prediction': 'Entailment'}, 'c2217d42-e90c-4ffe-b084-e653b9ace4d5': {'Prediction': 'Entailment'}, '080da381-b5dd-46d3-99c4-18112da153c1': {'Prediction': 'Entailment'}, 'c100a7cd-e3a2-4901-a3e0-12336f769c7b': {'Prediction': 'Entailment'}, 'ec1e269e-470d-43d9-8f23-8a19a5c96fcc': {'Prediction': 'Entailment'}, '21611c2a-e6eb-4012-a209-9b6781e1f260': {'Prediction': 'Entailment'}, 'd1b7105d-0b7d-4b10-92a7-d63243ff0629': {'Prediction': 'Entailment'}, '7f3fe97e-68ee-470f-b06e-21cdddb67aa8': {'Prediction': 'Entailment'}, 'ce8464bd-951e-44aa-97d9-10b917b055ce': {'Prediction': 'Entailment'}, '0131ebe3-746b-45a5-ba60-fdd326974fec': {'Prediction': 'Entailment'}, 'b1dd7632-ed92-40a9-9293-bce68619c658': {'Prediction': 'Entailment'}, '45ccd2c8-6e02-4f0f-a370-eed18d26e6dc': {'Prediction': 'Entailment'}, '4a15ec5e-4904-4f01-a0a2-c51e83c8c070': {'Prediction': 'Entailment'}, 'b9e29ea8-6847-40d4-b5c3-81c496101695': {'Prediction': 'Entailment'}, '2a2c16a7-f427-4fdb-8153-94aac304e4b8': {'Prediction': 'Entailment'}, '618a3ae1-b22c-4c35-86a6-190c1b5b5d21': {'Prediction': 'Entailment'}, 'e62f5a3f-0091-4980-9822-db8f4dc2502a': {'Prediction': 'Entailment'}, '4a41ac73-538a-43e5-b7ce-8c8e2d56286e': {'Prediction': 'Entailment'}, '75a65913-5655-4377-b441-ecdd4dd75175': {'Prediction': 'Entailment'}, '1329dec6-fb2c-4219-9db6-3fef9d94b316': {'Prediction': 'Entailment'}, '29b2fa29-5a76-4877-95bb-1a8de7973d33': {'Prediction': 'Entailment'}, '7edba90d-076d-4f55-b9d6-a1765ceb48bd': {'Prediction': 'Entailment'}, 'ba9daeb9-796d-49ab-a30c-4d8acbdf4d37': {'Prediction': 'Entailment'}, '1314146f-2869-4525-8034-7f732d238385': {'Prediction': 'Entailment'}, '7c7418d2-32d7-4517-874b-eb3db24ea16a': {'Prediction': 'Entailment'}, '1f6a14ae-e22b-4b40-b389-217570dbf38e': {'Prediction': 'Entailment'}, '5c1e360c-fd93-4dd4-b855-71ba416d34cb': {'Prediction': 'Entailment'}, 'c7a953b0-ac96-4e0a-9c1d-98cf8af2861d': {'Prediction': 'Entailment'}, '48f516ff-abb4-4312-9b00-02f53fb16218': {'Prediction': 'Entailment'}, '978d19fc-e7f6-485e-b8bd-cfcde06441ab': {'Prediction': 'Entailment'}, '0a6d1b4c-244e-44e2-a229-62e4cbdfa979': {'Prediction': 'Entailment'}, '9bcc31df-c1f6-4785-9235-f673213acf3a': {'Prediction': 'Entailment'}, '63a0a9fc-80b9-450f-b2c6-7aee37ce26a9': {'Prediction': 'Entailment'}, '75cf4ec2-9f2b-4d5b-8772-af247eaca07b': {'Prediction': 'Entailment'}, '553f00ea-5197-4233-b1e0-e5727856b599': {'Prediction': 'Entailment'}, '57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32': {'Prediction': 'Entailment'}, '215a5c4a-d90c-4500-8284-0679ce311734': {'Prediction': 'Entailment'}, 'e9a4bd91-f58b-4234-9037-75e0699d1bbd': {'Prediction': 'Entailment'}, '7d52734c-0801-413d-9ae2-d190b972cde5': {'Prediction': 'Entailment'}, '5de9caeb-9dd5-4535-8fe3-289450d9c626': {'Prediction': 'Entailment'}, 'bebfc78e-b35f-4677-8342-9567a7e795a1': {'Prediction': 'Entailment'}, 'faa65e54-aa04-4595-8dae-05cf00b4c887': {'Prediction': 'Entailment'}, '751fd763-89fa-4d52-8bda-f09b490a5e78': {'Prediction': 'Entailment'}, 'c40fdf91-9f81-454a-bba9-ec5c950cef6e': {'Prediction': 'Entailment'}, '31105b43-832b-48bc-a78d-ee90c155ca44': {'Prediction': 'Entailment'}, '49ba06b2-576d-4db2-80b6-51673416f2ba': {'Prediction': 'Entailment'}, '3cb71095-8e01-40dc-bbf5-eeffed55f354': {'Prediction': 'Entailment'}, '09fc4356-6154-427e-b710-ed5df6470aff': {'Prediction': 'Entailment'}, '446f3c69-0de5-475c-a8e2-ff40ece90672': {'Prediction': 'Entailment'}, 'cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2': {'Prediction': 'Entailment'}, 'f0e845f9-8991-45b5-a520-51e934756f7a': {'Prediction': 'Entailment'}, 'a0065d58-e03b-4dd0-9c81-cbbf651a6d45': {'Prediction': 'Entailment'}, 'b2cdbcb8-de26-4a44-8a94-dd68c13f7e41': {'Prediction': 'Entailment'}, '973f090a-8967-4d75-bb8e-6166c868337c': {'Prediction': 'Entailment'}, '79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2': {'Prediction': 'Entailment'}, '1d1f57f8-85f7-448c-a4bb-15957da568fd': {'Prediction': 'Entailment'}, '9f7d476e-9db3-4c00-abe6-4c2f0160470a': {'Prediction': 'Entailment'}, 'a5e388b9-da3c-437e-a6af-7ba76ad8bf1d': {'Prediction': 'Entailment'}, '3adcc8fc-b76b-407a-a006-729a13f571fb': {'Prediction': 'Entailment'}, '68379456-775b-463b-bfdb-d8aa42c9124b': {'Prediction': 'Entailment'}, '5d0ccb93-71ec-4079-92c6-d7cbf951a7bb': {'Prediction': 'Entailment'}, 'f04d9695-81b8-4d70-877b-59caddf901bd': {'Prediction': 'Entailment'}, 'f42e1874-343a-43ed-bb0c-884509c4793c': {'Prediction': 'Entailment'}, '30483d7e-7703-459c-bd10-e2bd259c2a4f': {'Prediction': 'Entailment'}, '7cde9a22-a91f-4feb-892d-7cbd35f96a27': {'Prediction': 'Entailment'}, '16c29502-4683-4087-9410-ff1b786556f5': {'Prediction': 'Entailment'}, '5c975af8-6b7f-4a5d-b4a6-257c76763ce9': {'Prediction': 'Entailment'}, '1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7': {'Prediction': 'Entailment'}, '8e91e404-086e-4063-8d54-83d1b8ebd969': {'Prediction': 'Entailment'}, 'b8322b23-a4f6-4cba-9761-be826b509de7': {'Prediction': 'Entailment'}, '4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3': {'Prediction': 'Entailment'}, '4b97a844-8d52-48bb-8eda-ca205268f016': {'Prediction': 'Entailment'}, '2a03c17f-3afe-40f1-a0db-4b876ee8c700': {'Prediction': 'Entailment'}, '3ba42f68-a643-4d10-afd0-cbb358d05a6f': {'Prediction': 'Entailment'}, '0a079cca-abde-42cf-9cec-a76e7a380e14': {'Prediction': 'Entailment'}, '9c033072-5f94-4d79-af47-126d531f0d6e': {'Prediction': 'Entailment'}, 'a52b2d4f-0b06-4960-a9c3-88cb92df0980': {'Prediction': 'Entailment'}, 'a792bbac-0e8a-4bf7-9cc5-56fad481e2fb': {'Prediction': 'Entailment'}, '1842904b-5371-49ee-b6f4-8831b879098b': {'Prediction': 'Entailment'}, '324562e6-2b61-4a07-b937-86f99689f2d5': {'Prediction': 'Entailment'}, '74e376d7-5713-43f3-93f1-9608059c9547': {'Prediction': 'Entailment'}, '0e609fad-9a28-4fb6-90b6-32a731e3b02c': {'Prediction': 'Entailment'}, '236780db-9e59-4dc9-8da0-e786287011cf': {'Prediction': 'Entailment'}, '6d621974-c719-46df-8a50-d94e49583e33': {'Prediction': 'Entailment'}, 'a9907a2e-254a-45ca-af50-3e44fd2f7af3': {'Prediction': 'Entailment'}, '40f699a1-fbc6-40de-8e80-85b28f71632f': {'Prediction': 'Entailment'}, '6499b181-7a23-4073-8459-ad46ff02b20f': {'Prediction': 'Entailment'}, '2da13cd4-7189-4f85-be4d-5c1e213ae293': {'Prediction': 'Entailment'}, 'a9bb6de9-c6f8-4c99-81cd-f101cbaab387': {'Prediction': 'Entailment'}, '7e5fd062-6ec3-480f-ab0e-e117eba2ffe7': {'Prediction': 'Entailment'}, '016943fa-57ea-4293-8131-03292ea1836c': {'Prediction': 'Entailment'}, '402f0dbf-cf67-4425-b300-a0a3df4d59d3': {'Prediction': 'Entailment'}, '62be4676-099f-4c42-8029-773af8fde6f7': {'Prediction': 'Entailment'}, '1180dd58-61b8-4c48-ab00-7d458e68c85b': {'Prediction': 'Entailment'}, '566bdc2d-7c4a-4547-87da-ac81447ecca8': {'Prediction': 'Entailment'}, 'd310ec4e-993e-4827-8dc5-9aca053972db': {'Prediction': 'Entailment'}, 'a5617ae4-05a3-42d0-9e14-141de5f8c010': {'Prediction': 'Entailment'}, '42d1fcd3-8faa-4065-bbba-42cc90ab67fb': {'Prediction': 'Entailment'}, 'd01fda83-5dc8-4ad5-92b8-7553dabd7046': {'Prediction': 'Entailment'}, '985bc5a0-bc21-447f-92f1-150e23ede3f5': {'Prediction': 'Entailment'}}\n"
     ]
    },
    {
     "ename": "FileNotFoundError",
     "evalue": "[Errno 2] No such file or directory: '/content/drive/MyDrive/Task-2-SemEval-2024/results.json'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mFileNotFoundError\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[15], line 2\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[38;5;28mprint\u001b[39m(Results)\n\u001b[1;32m----> 2\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m \u001b[38;5;28;43mopen\u001b[39;49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/content/drive/MyDrive/Task-2-SemEval-2024/results.json\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43mw\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m)\u001b[49m \u001b[38;5;28;01mas\u001b[39;00m jsonFile:\n\u001b[0;32m      3\u001b[0m     jsonFile\u001b[38;5;241m.\u001b[39mwrite(json\u001b[38;5;241m.\u001b[39mdumps(Results,indent\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m4\u001b[39m))\n",
      "File \u001b[1;32m~\\AppData\\Local\\Programs\\Python\\Python39\\lib\\site-packages\\IPython\\core\\interactiveshell.py:282\u001b[0m, in \u001b[0;36m_modified_open\u001b[1;34m(file, *args, **kwargs)\u001b[0m\n\u001b[0;32m    275\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m file \u001b[38;5;129;01min\u001b[39;00m {\u001b[38;5;241m0\u001b[39m, \u001b[38;5;241m1\u001b[39m, \u001b[38;5;241m2\u001b[39m}:\n\u001b[0;32m    276\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[0;32m    277\u001b[0m         \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mIPython won\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mt let you open fd=\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mfile\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m by default \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    278\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mas it is likely to crash IPython. If you know what you are doing, \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    279\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124myou can use builtins\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m open.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m    280\u001b[0m     )\n\u001b[1;32m--> 282\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m io_open(file, \u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "\u001b[1;31mFileNotFoundError\u001b[0m: [Errno 2] No such file or directory: '/content/drive/MyDrive/Task-2-SemEval-2024/results.json'"
     ]
    }
   ],
   "source": [
    "print(Results)\n",
    "with open(\"/content/drive/MyDrive/Task-2-SemEval-2024/results.json\",'w') as jsonFile:\n",
    "    jsonFile.write(json.dumps(Results,indent=4))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "d29f0add",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "F1:0.666667\n",
      "precision_score:0.500000\n",
      "recall_score:1.000000\n"
     ]
    }
   ],
   "source": [
    "def main():\n",
    "\n",
    "    gold = dev\n",
    "    results = Results\n",
    "    uuid_list = list(results.keys())\n",
    "\n",
    "    results_pred = []\n",
    "    gold_labels = []\n",
    "    for i in range(len(uuid_list)):\n",
    "        if results[uuid_list[i]][\"Prediction\"] == \"Entailment\":\n",
    "            results_pred.append(1)\n",
    "        else:\n",
    "            results_pred.append(0)\n",
    "        if gold[uuid_list[i]][\"Label\"] == \"Entailment\":\n",
    "            gold_labels.append(1)\n",
    "        else:\n",
    "            gold_labels.append(0)\n",
    "\n",
    "    f_score = f1_score(gold_labels,results_pred)\n",
    "    p_score = precision_score(gold_labels,results_pred)\n",
    "    r_score = recall_score(gold_labels,results_pred)\n",
    "\n",
    "    print('F1:{:f}'.format(f_score))\n",
    "    print('precision_score:{:f}'.format(p_score))\n",
    "    print('recall_score:{:f}'.format(r_score))\n",
    "\n",
    "if '__main__' == __name__:\n",
    "    main()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "048fa84b",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "import json\n",
    "import os\n",
    "import numpy as np\n",
    "\n",
    "Results = {}\n",
    "\n",
    "for i in range(len(uuid_list)):\n",
    "    primary_ctr_path = os.path.join(path, dev[uuid_list[i]][\"Primary_id\"] + \".json\")\n",
    "    \n",
    "    with open(primary_ctr_path) as json_file:\n",
    "        primary_ctr = json.load(json_file)\n",
    "    \n",
    "    primary_section = primary_ctr[dev[uuid_list[i]][\"Section_id\"]]\n",
    "    \n",
    "    # Fit the vectorizer on all sections in the training data\n",
    "    vectorizer = TfidfVectorizer().fit(primary_section + secondary_section)\n",
    "    \n",
    "    X_s = vectorizer.transform([statements[i]])\n",
    "    X_p_primary = vectorizer.transform(primary_section)\n",
    "    \n",
    "    primary_scores = cosine_similarity(X_s, X_p_primary)[0]\n",
    "    \n",
    "    if dev[uuid_list[i]][\"Type\"] == \"Comparison\":\n",
    "        secondary_ctr_path = os.path.join(path, dev[uuid_list[i]][\"Secondary_id\"] + \".json\")\n",
    "        \n",
    "        with open(secondary_ctr_path) as json_file:\n",
    "            secondary_ctr = json.load(json_file)\n",
    "        \n",
    "        secondary_section = secondary_ctr[dev[uuid_list[i]][\"Section_id\"]]\n",
    "        \n",
    "        X_p_secondary = vectorizer.transform(secondary_section)\n",
    "        secondary_scores = cosine_similarity(X_s, X_p_secondary)[0]\n",
    "        \n",
    "        # Combine and average the cosine distances\n",
    "        combined_scores = np.concatenate([secondary_scores, primary_scores])\n",
    "        score = np.average(combined_scores)\n",
    "    else:\n",
    "        score = np.average(primary_scores)\n",
    "\n",
    "    # Adjust the threshold based on your experiments\n",
    "    if score > 0.8:\n",
    "        Prediction = \"Contradiction\"\n",
    "    else:\n",
    "        Prediction = \"Entailment\"\n",
    "    \n",
    "    Results[str(uuid_list[i])] = {\"Prediction\": Prediction}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "3b4128d0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Best Precision: 0.5\n",
      "Best Recall: 1.0\n",
      "Best F1: 0.6666666666666666\n",
      "Best Threshold: 0.1\n"
     ]
    }
   ],
   "source": [
    "from sklearn.metrics import precision_score, recall_score, f1_score\n",
    "\n",
    "# Initialize variables to store the best metrics and threshold\n",
    "best_precision = 0\n",
    "best_recall = 0\n",
    "best_f1 = 0\n",
    "best_threshold = 0\n",
    "\n",
    "# Experiment with different threshold values\n",
    "for threshold in np.arange(0.1, 1.0, 0.1):\n",
    "    # Use the threshold in your existing code\n",
    "    if score > threshold:\n",
    "        Prediction = \"Contradiction\"\n",
    "    else:\n",
    "        Prediction = \"Entailment\"\n",
    "    \n",
    "    # Compute precision, recall, and F1\n",
    "        gold = dev\n",
    "    results = Results\n",
    "    uuid_list = list(results.keys())\n",
    "\n",
    "    results_pred = []\n",
    "    gold_labels = []\n",
    "    for i in range(len(uuid_list)):\n",
    "        if results[uuid_list[i]][\"Prediction\"] == \"Entailment\":\n",
    "            results_pred.append(1)\n",
    "        else:\n",
    "            results_pred.append(0)\n",
    "        if gold[uuid_list[i]][\"Label\"] == \"Entailment\":\n",
    "            gold_labels.append(1)\n",
    "        else:\n",
    "            gold_labels.append(0)\n",
    "            \n",
    "    y_true = gold_labels\n",
    "    y_pred = results_pred\n",
    "    \n",
    "    precision = precision_score(y_true, y_pred)\n",
    "    recall = recall_score(y_true, y_pred)\n",
    "    f1 = f1_score(y_true, y_pred)\n",
    "    \n",
    "    # Update the best metrics and threshold if necessary\n",
    "    if f1 > best_f1:\n",
    "        best_f1 = f1\n",
    "        best_precision = precision\n",
    "        best_recall = recall\n",
    "        best_threshold = threshold\n",
    "\n",
    "# Print the best metrics and threshold\n",
    "print(\"Best Precision:\", best_precision)\n",
    "print(\"Best Recall:\", best_recall)\n",
    "print(\"Best F1:\", best_f1)\n",
    "print(\"Best Threshold:\", best_threshold)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "eb856686",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
